Dexmethylphenidate Hydrochloride Tablet
Product Images NDC 10702-106

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Dexmethylphenidate Hydrochloride (NDC 10702-106). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Kvk-tech, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

6f4edd9f Figure 05

Label for Dexmethylphenidate Hydrochloride Tablets, 2.5 mg strength, in a round blue tablet form. The label indicates a package containing 100 tablets, for oral use, with the pharmacist instruction to dispense with an accompanying medication guide. The labeler is KVK-TECH, INC, manufactured in the USA, including storage instructions and child safety warnings. A barcode and other regulatory information are visible.*

FDA Label Image

6f4edd9f Figure 06

Label for Dexmethylphenidate Hydrochloride Tablets 5 mg oral tablets by KVK-Tech, Inc. The label shows round yellow tablets imprinted with "A2", indicates a package of 100 tablets for prescription use only, and includes dosage, storage, and safety instructions. The label also displays the NDC code 10702-0107-01 and manufacturing details.*

FDA Label Image

6f4edd9f Figure 07

Label for Dexmethylphenidate Hydrochloride Tablets, 10 mg strength, oral tablets. The label shows the product name prominently with strength in a bold box, indicates 100 tablets per container, and states 'Rx Only'. It also includes storage instructions, a pharmacy dispensing advisory, and labeling by KVK-TECH, INC, Newtown, PA. The label features barcodes, lot and expiration date spaces, and regulatory warnings to keep out of reach of children.*

FDA Label Image

Chemical Formula Figure 01

Chemical structure of Dexmethylphenidate Hydrochloride showing a piperidine ring, a phenyl group, and ester functional group with hydrochloride salt.*

FDA Label Image

Company Logo Figure 04

FDA Label Image

Table 3 Figure 02

Table summarizing efficacy results from an ADHD acute-phase study in pediatric patients aged 6 to 17. It compares treatment effects of Focalin 5-20 mg/day versus placebo on Teacher SNAP-ADHD Total Scores, showing mean baseline scores and mean change from baseline at week 4 with standard deviations and sample sizes.*

FDA Label Image

Table 4 Figure 03

A data table summarizing efficacy results from an ADHD randomized withdrawal study in pediatric patients aged 6 to 17 years (Study 2). It compares treatment groups using Focalin 5-20 mg/day versus placebo, showing the number and proportion of treatment failures as 6/35 (17.1%) for Focalin and 25/40 (62.5%) for placebo. Footnotes explain statistical significance and data exclusions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.